Latest Drug design Stories
Company showcase featuring Ed Addison to take place on Tuesday, May 12 from at 14:10 RESEARCH TRIANGLE PARK, N.C., April 30, 2015 /PRNewswire/ -- Ed Addison, CEO of Cloud Pharmaceuticals,
Structures of human P2Y1 receptor bring new excitement to GPCR research BEIJING, March 30, 2015 /PRNewswire/ -- A team of Chinese and US scientists has determined the high-resolution
Breakthrough computer-based drug discovery process enabled drug design of MTH1 inhibitors RESEARCH TRIANGLE PARK, N.C., March 17, 2015 /PRNewswire/ -- Cloud Pharmaceuticals, a therapeutics
RESEARCH TRIANGLE PARK, N.C., Feb.
LONDON and BOSTON, January 22, 2015 /PRNewswire/ -- Stable Receptor, X-ray Structure and Hit Series Generated for PAR2, a Previously
RESEARCH TRIANGLE PARK, N.C., Sept.
NEW YORK, Sept.
Phase I Project to Focus on Advanced Molecular Search Models for the Inverse Design Computational Drug Discovery Platform RESEARCH TRIANGLE PARK, N.C., July 29, 2014 /PRNewswire/ --
Dehydrons are defects in protein structure that promote protein associations.
- A young chicken: also used as a pet name for children.